Comparison of the ultrashort gonadotropin-releasing hormone agonist-antagonist protocol with microdose flare-up protocol in poor responders: a preliminary study

Bülent Berker¹, Candan İltemir Duvan², Cemil Kaya³, Ruşen Aytaç¹, Hakan Şaturoğlu¹
¹Centre of Artificial Reproduction, Ankara University, Ankara, Turkey
²Centre of Artificial Reproduction, Fatih University, Ankara, Turkey
³Department of Obstetrics and Gynecology, Ufuk University, Ankara, Turkey

Abstract

Objective: To determine the potential effect of the ultrashort gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol versus the microdose GnRH agonist protocol in poor responders undergoing intracytoplasmic sperm injection (ICSI).

Material and Methods: The patients in the Agonist-Antagonist Group (n=41) were administered the ultrashort GnRH-agonist/ antagonist protocol, while the patients in the Microdose Group (n=41) were stimulated according to the microdose flare-up protocol. The mean number of mature oocytes retrieved was the primary outcome measure. Fertilization rate, implantation rate per embryo and clinical pregnancy rates were secondary outcome measures.

Results: There was no difference between the mean number of mature oocytes retrieved in the two groups. There were also no statistical differences between the two groups in terms of peak serum E₂ level, canceled cycles, endometrial thickness on hCG day, number of 2 pronucleus and number of embryos transferred. However, the total gonadotropin consumption and duration of stimulation were significantly higher with the Agonist-Antagonist Group compared with the Microdose Group. The implantation and clinical pregnancy rates were similar between the two groups.

Conclusion: Despite the high dose of gonadotropin consumption and longer duration of stimulation with the ultrashort GnRH agonist/ antagonist protocol, it seems that the Agonist-Antagonist Protocol is not inferior to the microdose protocol in poor responders undergoing ICSI.

Key words: Poor responders, mature oocytes, Agonist-Antagonist protocol, microdose flare-up protocol

Accepted: 19 November, 2010

Introduction

The management of the poor-responder patients still presents a challenging and frustrating problem in assisted reproductive technologies (ART). Poor ovarian response is unfortunately associated with a high rate of cycle cancellation and decreased pregnancy rates (1, 2). Although there is no universally accepted definition for poor responders, a poor response to controlled ovarian hyperstimulation (COH) might occur in a significant number of women undergoing ART, with a percentage ranging between 10% and 25% (2, 3). The ideal approach to patients who respond poorly to traditional COH...
regimens in preparation for ART has not been clearly defined. Different treatment interventions have been proposed for these women to overcome the poor ovarian response during COH. These options consisted of pituitary down-regulation protocols as gonadotropin-releasing hormone agonist (GnRH-a) stop protocols, microdose GnRH-a flare-up protocols or GnRH antagonist protocols and also adjuvant therapy regimens including growth hormone and letrozol (4, 5).

The most prevalent approaches for treating poor responder patients are microdose GnRH-a “flare” (6, 7) and GnRH antagonist protocol (8, 9). According to several studies, microdose GnRH-a flare-up regimes seem to be more successful in terms of ovarian response and/or pregnancy rates (4, 10). The basic hypothesis of this approach is the administration of the minimal dose of GnRH-a necessary to induce gonadotropin release while minimizing premature ovulation. The other attractive treatment option for poor responders is the GnRH antagonist protocol. These agents act to block the pituitary gonadotrop receptors rapidly without any associated stimulatory effects. As the initiations of the GnRH-antagonists occur after the beginning of gonadotropin stimulation, their impact on early follicular recruitment is minimal (8).

Even in the original manuscript of Surrey describing the microdose flare protocol, no change in follicular phase testosterone, LH, and progesterone levels were reported, but there are still some concerns about these issues (7, 11, 11-13). In a similar fashion, the GnRH antagonist protocol exposes the maturing oocytes to the patient’s own endogenous androgen production, which is detrimental during the 6th to 7th days of stimulation before development of a mature follicle (14). In addition, the impact of these protocols on endometrial receptivity also remains controversial (15, 16). As a result, neither of these protocols has been effective in improving ART outcomes in this subgroup of patients (7, 17, 18).

The idea of the combination of the microdose GnRH-a flare-up and GnRH antagonist protocol to minimize these detrimental effects and to combine the beneficial effects of these two stimulation protocols for poor responders was first presented by Berger et al. as a novel protocol - the “Agonist-Antagonist Protocol (AAP)” (19).

Up to date, there have been no randomized, prospective published data comparing the novel AAP and microdose GnRH-flare-up protocols in poor responders undergoing intracytoplasmic sperm injection (ICSI). Therefore, in this randomized prospective study, we aim to compare the efficacy of the ovarian stimulation by ultrashort GnRH agonist-antagonist with microdose flare-up protocol in poor responders undergoing ICSI.

Material and Methods

Patients and study design

Between September 2006 and April 2008, a total of 82 poor responder patients who underwent intracytoplasmic sperm injection cycles (ICSI) were included. All patients underwent precycle ovarian reserve testing, which included an assessment of cycle day 3 serum follicle-stimulating hormone (FSH) and E2 levels and a measurement of ovarian volume and number of antral follicles counting by transvaginal ultrasound during the follicular phase. Criteria for classification as a poor responder included at least one of the following: day 3 serum FSH level >10 mIU/mL, <6 total antral follicles, prior cycle cancellation, prior poor response to COH (peak E2 <500 pg/mL and/or <6 oocytes retrieved), and age >41 (18). The study was approved by the Institutional Review Board of the University. All patients received adequate counseling regarding the stimulation regimens and signed informed consent forms.

Patients were excluded from the study if they had only one ovary, a body mass index higher than 30, polycystic ovary syndrome, stage III–IVendometriosis, endocrine or metabolic disease, chromosomal disorders and patients whose partners were azospermic.

A method of computer-generated block randomization using sealed envelopes was employed. Patients were assigned in a 1:1 ratio to either an ultrashort GnRH agonist/GnRH antagonist group or microdose flare up protocol. Sealed envelopes with treatment allocation instructions were opened on the day of stimulation initiation by a nurse who assigned participants to their groups and was responsible for coding protection.

Treatment protocols

The patients in the ultrashort GnRH agonist/GnRH antagonist group (n=41) were administered the ultrashort GnRH-agonist/ GnRH antagonist protocol. The ultrashort GnRH-agonist/ GnRH antagonist protocol entailed the administration of leuprolide acetate (LA, Lucrin; Abbott, Cedex, France) at 40 microg sc/bid, started on the second day of menses and continued for 3 consecutive days, followed by gonadotropins, which were initiated on the last day of LA administration with maximal doses continuing until hCG day. Once the leading follicle had reached a size of 14 mm, cotreatment was initiated with the GnRH-antagonist cetrotrelx (Cetrotide; Serono, Turkey) at 0.25 mg/day, which was continued up to hCG injection. A schematic for this protocol is provided in Figure 1.

The patients in the Microdose Group (n=41), who started to use 40 microg sc/bid LA on the second day of menses and two days after initiation of GnRH-a, gonadotropin stimulation was initiated and continued until hCG day. A schematic representation for this protocol is provided in Figure 2. In general, the starting dose of recombinant FSH (Gonal-F; Serono, Istanbul, Turkey) was determined depending on the age, body mass index and ovarian response to previous cycle (if present) and increased to a maximum of 450 IU/day depending on the ovarian response. The dosage of gonadotrophins was individualized after day 5 according to ultrasonographic and hormonal follow-ups of the follicular growth. Once at least three follicles >17 mm in diameter were achieved, 10,000 IU of human chorionic gonadotrophin (Choragon, Ferring, Kiel, Germany) were administered and transvaginal ultrasound guided oocyte recovery was scheduled for 35.5 h later.

Embryo culture and transfer

Standard intracytoplasmic sperm injection (ICSI) was performed as clinically appropriate. Gametes and embryos were cultured in a sequential G medium (Vitrolife, Englewood, CO) and incubated in 6% CO2, 5% O2, and 89% N2. Embryo transfer was performed on day 3 after oocyte collections. Embryo transfers were performed under ultrasound guidance using a Wallace catheter (Marlow, Willoughby, OK). Luteal support was given by daily vaginal progesterone (crinone %8 gel, Serono). Luteal support was initiated on the day of oocyte retrieval and continued
Figure 1. Schematic representation of the Agonist-Antagonist Protocol

Figure 2. Schematic representation of the Microdose GnRH-a flare-up protocol
until the day of pregnancy testing and if the test was positive, progesterone treatment was continued up to 12 gestational weeks. Pregnancy tests were performed 14 days after oocyte retrieval. Clinical pregnancies were confirmed by transvaginal ultrasound examination at 4.5 weeks from oocyte retrieval with the number of gestational sacs and cardiac activity noted. FSH was measured by a chemiluminescent immunometric assay with Immulite One, Bio-DPC, Siemens, USA. Analytical sensitivity: 0.1 mIU/ml. The inter assay and intra assay coefficients of variation were 5.6% and 3.1%.

Statistical analysis

Although the primary aim of this study was to compare the overall pregnancy rate per groups, to assess a difference in pregnancy rates between the protocols, a prior power calculation estimated that any sample size of between 160 and 348 would show a 10% difference with 80% power (α=0.05). Considering the rare occurrence of poor responders, it should take a considerably long time to be able to collect large samples in this subject, so we preferred to focus on oocyte numbers as a main outcome measure. The primary aim of this study was to compare by means of the number of mature oocytes A total sample size of 54 cases (27 for Agonist-Antagonist Group, 27 for Microdose Group) was required to detect a difference in means of 1.0 (SD=1.58) with a power of 80% at the 5% significance level using a two-sided Mann-Whitney test, assuming that the actual distribution is double exponential.

Statistical analysis was performed by Statistical Package for Social Sciences (SPSS) 11.5 software (SPSS Inc., Chicago, IL, United States). Whether the continuous variables were normally distributed or not were determined by using Shapiro Wilk test. Continuous variables were expressed as mean±standard deviation or median (minimum-maximum), where applicable. Nominal data were presented as the number of cases and (%). Whereas the differences between groups regarding normally distributed data were tested by Student’s t test, non-normally distributed data were evaluated by Mann Whitney U test. Nominal data were analyzed by Pearson Chi-square test. A p value less than 0.05 was considered as statistically significant.

Results

A total of 82 poor responder patients underwent 78 COH-ICSI cycles. Of these patients, 41 received the ultrashort GnRH agonist/GnRH antagonist protocol and 41 received the microdose flare-up protocol. The cycle cancellation was done for two patients in the AAP (n=39) group (one due to poor folliculogenesis, and one to fertilization failure), two patients in the Microdose Group (n=39, one cycle owing to premature LH surge, one cycle owing to poor folliculogenesis). Cycle cancellation rates were similar in the groups.

The mean number of mature oocytes retrieved was similar in the two groups (7.1±4.9 in AAP Group; 7.4±6.0 in Microdose Group; p>0.05). There were no statistical differences in age, BMI, day 3 FSH and estradiol levels between the two groups. Demographic data of the patients are displayed in Table 1. There were also no statistical differences between the two groups in terms of peak E2 level, endometrial thickness on hCG day, number of 2PN and number of embryos transferred. However, the duration of stimulation (10.51±2.4 vs. 9.05±2.61, respectively) and total consumption of the gonadotrophin doses (3635.93±1627.59 v. 2327.02±929.46; p=0.004) were significantly higher in the AAP Group (Table 2). The rate of top-quality embryo (Grade A; at least seven cells and <10% fragmentation on day 3) transferred, fertilization rate and implantation rate per embryo were similar between the groups (Table 3). However, pregnancy rate was higher in the microdose GnRH-a flare-up protocol than in AAP, but it did not reach the significant level (19.5% vs 26.3%, respectively).

Discussion

To the best of our knowledge, this is the first study comparing the AAP with the microdose GnRH-a flare-up protocol in poor responders. In the current study, we showed that the mean number of mature oocytes retrieved were similar between two groups. The results of our study further indicated that clinical pregnancy rates were also similar between the groups. The idea of minimizing the dose of the GnRH agonist agents created the so-called ‘mini’ and ‘micro’ dose flare-up GnRH

<table>
<thead>
<tr>
<th>Table 1. Demographic characteristics of the patients in both groups</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Agonist-Antagonist</strong></td>
</tr>
<tr>
<td>Number of patients (n)</td>
</tr>
<tr>
<td>Number of cycles (n)</td>
</tr>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>Number of patients aged &gt;35(years)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
</tr>
<tr>
<td>Infertility period (years)</td>
</tr>
<tr>
<td>Day 3 FSH (mIU/mL)</td>
</tr>
<tr>
<td>Number of patients &gt;FSH 10 (n)</td>
</tr>
<tr>
<td>Day 3 Estradiol (pgmol/L)</td>
</tr>
<tr>
<td>Cycle number</td>
</tr>
</tbody>
</table>

*p*Statistical significance was defined as *p*<0.05. Data were shown as mean±SD. Groups were compared using Student’s t or Mann Whitney U test, where appropriate.
agonist regimens. A microdose flare-up regimen has been proposed and used successfully in poor responders. The basic hypothesis of this approach is the administration of the minimal dose of GnRH-a necessary to induce gonadotropin release while minimizing premature ovulation. This approach takes advantage of the initial release of endogenous gonadotropins induced by low-dose GnRH-a administration in the early follicular phase, in an effort to enhance response to the subsequent administration of exogenous gonadotropins (7, 18, 20). Although this flare effect enhances follicular recruitment, it can result in premature luteinization and thus compromise the cycle (21). This approach has also some disadvantages such as increased serum LH levels, with a concomitant increase in serum progesterone and testosterone levels during the early follicular maturation (i.e., flare effect), which in turn may affect oocyte quality (11-13).

The incorporation of GnRH antagonists represents an appealing alternative to agonists in the management of the poor responder. The addition of the GnRH antagonist to stimulation protocols prevents premature LH surges, without causing suppression in the early follicular phase, a crucial time for poor-responder patients (22). The results of GnRH antagonists for poor responders indicate the possibility of reducing the amount of gonadotropins, the length of stimulation, the number of cancelled cycles, and the overall cost normally associated with the long protocol (23-27). However, the issue of the reported lower clinical pregnancy and implantation rates in the earlier studies comparing antagonist and agonist protocols is still not resolved. In the literature, there are several controlled studies comparing microdose flare and antagonist protocols and antagonist plus leetrozole in the recent literature. For example, Demirol et al. reported that the microdose flare-up protocol seems to have a better outcome in poor-responder patients, with a significantly higher mean number of mature oocytes retrieved and higher implantation rate. (28). In another study, Malmusi et al. also reported that, in terms of mature oocytes retrieved, fertilization rate, and top-quality embryos transferred in poor-responder patients, the flare-up protocol appears to be more effective than the GnRH-antagonist protocol (29). On the other hand, Kahraman et al. found that the microdose GnRH-a flare-up protocol and multiple dose GnRH antagonist protocol seem to have similar efficacy in improving treatment outcomes of poor responder patients (30).

Schoolcraft et al. also compared the efficacy of a microdose GnRH agonist flare (ML) with a GnRH antagonist/letrazole (AL) protocol in poor responders, and reported that stimulation between the microdose and antagonist-letrazole protocols were equivalent, with the exception of peak E₂ levels. However, the higher ongoing pregnancy rates and trend toward superior implantation rates would suggest that microdose represents a preferred approach for the poor responder (4). However, in another study from Yarali et al. It was reported that, in terms of the high fertilization rate and the rate of at least one top-quality embryo transferred in the GnRH antagonist/letrazole protocol, compared with the mirodose protocol the GnRH antagonist/letrazole protocol is an effective protocol that may be used in poor ovarian responders for ICSI (31).

Although as in the above studies, several trials investigated the microdose flare and antagonist protocols or antagonist plus
lestrazole protocol in poor responders, only a limited number of studies in the literature investigated combining the ultrashort GnRH agonist-antagonist protocols in poor responders (17, 19, 32). The report by Berger et al. (19), which is the first report dealing with the AAP protocol, was presented only as a meeting abstract, so no data exists concerning the stimulation characteristics of the control cycles. Similarly, Orvieto et al. (17) evaluated the role of the ultrashort GnRH-agonist flare protocol combined with the flexible multidose GnRH-antagonist protocol in patients who had responded poorly to a previous IVF attempt. In contrast to our study, their AAP protocol entailed depot analog (tripotrenol 0.1 mg/day) as a GnRH-a. In addition, they did not report any information regarding the patients’ previous stimulation protocols. In 2005, Erden et al. in their retrospective study, compared the Agonist-Antagonist Protocol and microdose flare-up protocols in poor responder IVF patients (32). They reported that there were higher peak estradiol levels, more mature and fertilized oocytes and higher clinical pregnancy rates in the Agonist-Antagonist Protocol. Unfortunately, this study was presented only as an oral presentation. All the above studies had found statistically significantly higher numbers of oocytes retrieved and embryos transferred in the ultrashort GnRH agonist-antagonist group. In contrast to previous studies, we did not detect any differences in terms of stimulation and reproductive outcome parameters. The small number of patients in the studies with differences in the treatment period and in different antagonist protocols may explain these discrepancies. In addition, one of the difficulties in critically evaluating various COH protocols is the lack of a single universally accepted definition of ‘poor responder’ (5). A variety of criteria have been used alone or in combination as inclusion criteria for proposed protocols. In our study, in contrast to the previous studies, not only the previous IVF failure but other poor response markers were also used as inclusion criteria. It is possible that results may differ with the application of more strict criteria for this patient group. However, the definitions for poor responders employed in this trial are consistent with those employed in Schoolcraft et al.’s previously published evaluation of a microdose flare-up regime (18).

In this study, the women in the ultrashort GnRH agonist/GnRH antagonist protocol had a longer treatment duration and required significantly more gonadotropin, but had the same mean number of metaphase II oocytes retrieved as did women in the microdose flare-up protocol. Thus, the follicular response was slower in the ultrashort GnRH agonist/GnRH antagonist group. Prolongation of the follicular phase in patients stimulated with rec-FSH and GnRH antagonist for IVF does not affect oocyte or embryo quality (33). In our results, the implantation and clinical pregnancy rate per cycle were similar. As a result of our previous study, we thought that this preference should not affect the outcomes of the microdose protocol negatively (34).

The major weakness of our study is the limited number of couples undergoing the ICSI procedures investigated. Thus, we consider that the results of this study could be significant if the number of patients per group were increased.

In conclusion, the most convenient COH protocol for poor responder patients is still unclear. According to our preliminary study, in terms of primary outcome measure, this protocol seems to be equal to the microdose protocol, but in terms of secondary outcome measures there are statistically significant differences in terms of gonadotropin consumption and duration of stimulation in favor of the microdose flare protocol. Hence, we may consider that, in the event of high doses of gonadotropin consumption and long duration of stimulation, AAP protocols seem to be valuable alternatives for poor responders. This novel protocol may be offered especially to patients with a history of a failure with the microdose flare-up protocol. However, before making any recommendations; further large prospective randomized studies are needed to elucidate the exact role of the Agonist-Antagonist Protocols in poor responders.

Conflict of interest
No conflict of interest is declared by authors.

References


